Skip to main content
Evidence Snapshot

IgG receptor FcRn large subunit p51

CHEMBL5966 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:52:06Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5966
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats IgG receptor FcRn large subunit p51 as ChEMBL target CHEMBL5966, mapped to UniProt P55899. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
IgG receptor FcRn large subunit p51
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5966
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P55899
IgG receptor FcRn large subunit p51
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why IgG receptor FcRn large subunit p51 matters

As of 2026-09-13

IgG receptor FcRn large subunit p51 is reviewed as IgG receptor FcRn large subunit p51 (UniProt P55899); IgG receptor FcRn large subunit p51 shows approved-linked disease relevance led by Myasthenia gravis. 5 more disease programs remain visible in the same review block.; 5 linked drugs keep this evidence frame grounded.; the current evidence base includes 0 approved drugs, 208 compounds, and 13 assays, with lead potency reaching pChEMBL 8.8.

Disease context
Myasthenia gravis

IgG receptor FcRn large subunit p51 shows approved-linked disease relevance led by Myasthenia gravis. 5 more disease programs remain visible in the same review block. 5 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include BATOCLIMAB, EFGARTIGIMOD ALFA, NIPOCALIMAB.

Start review with Myasthenia gravis because it currently carries approved-linked support. Linked drugs include BATOCLIMAB, EFGARTIGIMOD ALFA, NIPOCALIMAB, ORILANOLIMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 5 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 0 approved drugs, 208 compounds, and 13 assays for this target. The dominant activity type is KD. CHEMBL1090633 is the current potency anchor at pChEMBL 8.8.

Use CHEMBL1090633 as the tractability anchor when discussing potency (pChEMBL 8.8).

Activity source · ChEMBL 36 via Core Engine
pChEMBL 8.8
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why IgG receptor FcRn large subunit p51 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P55899, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why Myasthenia gravis is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

208
Total Compounds
13
Total Assays
0
Approved Drugs
IC50: 208.0, KD: 215.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL1090633
 8.8 IC50 —
No preferred name
CHEMBL1090632
 8.6 IC50 —
No preferred name
CHEMBL1090970
 8.6 IC50 —
No preferred name
CHEMBL2304309
 8.6 IC50 —
No preferred name
CHEMBL1090278
 8.4 IC50 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:52:06Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5966